Immune Response Nurses Protein Scientist 
pharmaphorum
NOVEMBER 2, 2020
In January, Google DeepMind debuted AlphaFold, a deep-learning system that predicts the structure of several under-studied proteins, including those associated with COVID-19. Scientists are using AI to sift through existing literature on a disease and study its disease’s structure. These chatbots can nurse and triage patients.
The Pharma Data
NOVEMBER 19, 2020
A study out of Rutgers University found that healthcare staffers, especially nurses, have a higher prevalence of COVID-19 than non-healthcare workers. Of the 40 healthcare workers who tested positive of the study group, 25 were nurses. It may also improve the immune response that protects the connections between neurons.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 29, 2020
The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. futility analysis). .
The Pharma Data
DECEMBER 17, 2020
To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.
XTalks
SEPTEMBER 14, 2020
The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus.
The Pharma Data
NOVEMBER 20, 2020
The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. About Regeneron.
The Pharma Data
NOVEMBER 21, 2020
The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
Expert insights. Personalized for you.
132 
Let's personalize your content